RxDoctor Payments Data

Amber Lane

Optometrist · Hopkinsville, KYNPI 1144518010

Payments from drug & device makers

$940in general payments, 2019–2025

Across 42 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$236
  • Alcon$116
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$105
  • Novartis$101
  • Bausch & Lomb Americas Inc.$89
  • Dompe US, Inc.$88
  • plus $203 from 5 others

What the payments were for

  • Food & beverage$940100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$940 in reported general payments places this provider in the 55th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$153,695
Medicare patients
823
Services billed
5,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$46,142
LumiganBimatoprost63$25,353
VyzultaLatanoprostene Bunod49$19,630
CombiganBrimonidine Tartrate/Timolol39$15,287
Cyclosporine23$14,150
MieboPerfluorohexyloctane/Pf16$12,007
Travoprost55$11,997
Latanoprost352$3,928
SimbrinzaBrinzolamide/Brimonidine Tart11$2,188
Prednisolone Acetate55$1,658
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat67$1,359
Dorzolamide Hcl55$1,111
Brimonidine Tartrate130$1,107
Fluorometholone14$904
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$89$31,63765 claims
AlconSimbrinza$116$2,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Hopkinsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →